Skip to main content

Endometrial clinical trials: recruitment closed

ENGOT-en7 / AtTEnd | MaNGO Study |

STATUS: Recruitment completed

SPONSOR: Mario Negri Institute for Pharmacological Research (IRFMN)
LEAD GROUP: MaNGO
ENGOT Model: A
TITLE: Atezolizumab Trial in Endometrial cancer. Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer
ClinicalTrials.gov ID: NCT03603184
MaNGO sites (click to see the list on clinicaltrials.gov)

Sinossi  (click to see pdf)

Updates  (click to see the Newsletter)

ESMO 2023  (click to see the abstract)

Lancet Oncology Manuscript 2024 (click to see the link)

ENGOT-en11 / MK-3475-B21 / KEYNOTE-B21

STATUS: Recruitment completed

SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (GOG-3053)
ClinicalTrials.gov ID:  NCT04634877
MaNGO sites (click to see the list)

ENGOT-en12 / POD1UM-204

STATUS: Recruitment completed

SPONSOR: Incyte Corporation
LEAD GROUP: NOGGO
ENGOT Model: C
TITLE: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy
ClinicalTrials.gov ID: NCT04463771
MaNGO sites (click to see the list)

ENGOT-en15 / GOG-3064

STATUS: Recruitment completed

SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: MITO
ENGOT Model: C
TITLE: A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
ClinicalTrials.gov ID: NCT05173987
MaNGO sites (click to see the list)